Celgene Co. (NASDAQ:CELG) Shares Sold by Means Investment CO. Inc.

Means Investment CO. Inc. lowered its holdings in shares of Celgene Co. (NASDAQ:CELG) by 12.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,033 shares of the biopharmaceutical company’s stock after selling 1,400 shares during the period. Means Investment CO. Inc.’s holdings in Celgene were worth $1,082,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Lindbrook Capital LLC increased its holdings in shares of Celgene by 14.2% in the 3rd quarter. Lindbrook Capital LLC now owns 829 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 103 shares in the last quarter. Hendley & Co. Inc. increased its holdings in shares of Celgene by 0.3% in the 3rd quarter. Hendley & Co. Inc. now owns 38,282 shares of the biopharmaceutical company’s stock valued at $3,801,000 after purchasing an additional 105 shares in the last quarter. Berman Capital Advisors LLC increased its holdings in shares of Celgene by 11.3% in the 2nd quarter. Berman Capital Advisors LLC now owns 1,096 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 111 shares in the last quarter. Bbva USA Bancshares Inc. increased its holdings in shares of Celgene by 0.8% in the 2nd quarter. Bbva USA Bancshares Inc. now owns 13,271 shares of the biopharmaceutical company’s stock valued at $1,227,000 after purchasing an additional 111 shares in the last quarter. Finally, Plancorp LLC increased its holdings in shares of Celgene by 5.1% in the 2nd quarter. Plancorp LLC now owns 2,336 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 113 shares in the last quarter. Hedge funds and other institutional investors own 72.06% of the company’s stock.

A number of equities analysts have recently issued reports on CELG shares. Mizuho reiterated a “hold” rating and issued a $100.00 price target on shares of Celgene in a report on Sunday, October 20th. BidaskClub upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 price target for the company in a report on Tuesday, July 23rd. Standpoint Research downgraded shares of Celgene from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Finally, ValuEngine downgraded shares of Celgene from a “sell” rating to a “strong sell” rating in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, nineteen have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. Celgene has a consensus rating of “Hold” and an average price target of $97.31.

In other news, insider Terrie Curran sold 11,338 shares of Celgene stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the completion of the sale, the insider now directly owns 13,493 shares in the company, valued at $1,325,957.11. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.39% of the company’s stock.

NASDAQ:CELG traded up $0.42 during mid-day trading on Tuesday, hitting $109.99. 262,053 shares of the company’s stock traded hands, compared to its average volume of 4,190,941. The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.80 and a current ratio of 2.89. The firm’s 50 day simple moving average is $102.94 and its 200 day simple moving average is $96.92. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $109.75. The company has a market cap of $77.96 billion, a PE ratio of 14.45, a price-to-earnings-growth ratio of 0.52 and a beta of 1.41.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $2.99 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.70 by $0.29. The firm had revenue of $4.52 billion during the quarter, compared to the consensus estimate of $4.39 billion. Celgene had a net margin of 34.63% and a return on equity of 78.15%. The firm’s revenue for the quarter was up 16.1% on a year-over-year basis. During the same period last year, the firm posted $2.29 EPS. On average, research analysts expect that Celgene Co. will post 10.7 earnings per share for the current fiscal year.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Article: What moving averages are used to define a golden cross?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.